About Tourmaline Bio Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with ...

Novartis (NYSE:NVS) to acquire Tourmaline Bio (NASDAQ:TRML) for $48.00 per share in cash, or a total equity value of approximately $1.4 billion, the companies said on Tuesday. The deal underscores the ...

Tourmaline Bio, Inc.'s share price dropped by 37% after Chugai's Enspryng, an IL-6 blocker, failed to meet expectations in a study on myasthenia gravis. Tourmaline is developing TOUR006, its own IL-6 ...

Shares of Tourmaline Bio surged in premarket trading on Tuesday after the US-based biotechnology company agreed to be acquired by Swiss pharmaceutical major Novartis for approximately $1.4 billion.

Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease Pacibekitug is a promising ...

Basel, October 22, 2025 - Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with ...

Tourmaline Bio (TRML) has been catching investor attention recently, even without a specific event driving the headlines. Sometimes, stocks start to move or attract renewed interest for reasons that ...

Truist Financial analyst Robyn Karnauskas maintained a Buy rating on Tourmaline Bio (TRML – Research Report) today. The company’s shares closed last Friday at $24.67. According to TipRanks, Karnauskas ...

Basel, October 28, 2025 - Novartis today announced that it has successfully completed its acquisition of Tourmaline Bio, Inc. (“Tourmaline”). With the completion of the acquisition, shares of common ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients ...